Neil W. Gibson

7.5k total citations · 2 hit papers
86 papers, 5.2k citations indexed

About

Neil W. Gibson is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Neil W. Gibson has authored 86 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 27 papers in Organic Chemistry and 18 papers in Oncology. Recurrent topics in Neil W. Gibson's work include Cancer therapeutics and mechanisms (23 papers), Bioactive Compounds and Antitumor Agents (15 papers) and Synthesis and Biological Evaluation (11 papers). Neil W. Gibson is often cited by papers focused on Cancer therapeutics and mechanisms (23 papers), Bioactive Compounds and Antitumor Agents (15 papers) and Synthesis and Biological Evaluation (11 papers). Neil W. Gibson collaborates with scholars based in United States, United Kingdom and Canada. Neil W. Gibson's co-authors include David Ross, John D. Haley, Elizabeth Buck, David Siegel, Kenneth K. Iwata, Stuart Thomson, Filippo Petti, Graeme Griffin, Eric Brown and Alexandra Eyzaguirre and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Biochemistry.

In The Last Decade

Neil W. Gibson

86 papers receiving 5.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

2005 525 citations Stuart Thomson, Elizabeth Buck et al. Cancer Research profile →
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 335 citations Neil W. Gibson et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil W. Gibson United States	34	3.4k	1.7k	999	832	802	86	5.2k
Graziella Pratesi Italy	42	3.7k 1.1×	3.9k 2.3×	532 0.5×	1.1k 1.3×	758 0.9×	147	6.7k
Daniel C. Chan United States	42	3.0k 0.9×	1.6k 1.0×	1.4k 1.4×	622 0.7×	339 0.4×	82	5.3k
Gary A. Piazza United States	48	3.5k 1.0×	1.5k 0.9×	536 0.5×	1.1k 1.4×	1.2k 1.5×	171	6.9k
Rosanna Supino Italy	37	3.0k 0.9×	1.7k 1.0×	345 0.3×	803 1.0×	593 0.7×	109	4.9k
Angela Brodie United States	52	3.2k 1.0×	1.7k 1.0×	2.0k 2.0×	1.2k 1.5×	654 0.8×	132	7.8k
Dajun Yang China	39	3.5k 1.0×	2.0k 1.2×	884 0.9×	810 1.0×	735 0.9×	194	5.8k
Franca Formelli Italy	42	3.8k 1.1×	1.3k 0.7×	354 0.4×	683 0.8×	293 0.4×	125	5.8k
Massimo Broggini Italy	48	4.8k 1.4×	3.1k 1.8×	1.1k 1.2×	1.4k 1.7×	451 0.6×	236	7.6k
Wilbur R. Leopold United States	32	2.9k 0.9×	2.5k 1.5×	1.1k 1.1×	532 0.6×	1.0k 1.3×	65	5.4k
Paola Perego Italy	47	5.8k 1.7×	4.2k 2.4×	1.3k 1.3×	1.5k 1.9×	905 1.1×	177	9.2k

Countries citing papers authored by Neil W. Gibson

Since Specialization

Citations

This map shows the geographic impact of Neil W. Gibson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil W. Gibson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil W. Gibson more than expected).

Fields of papers citing papers by Neil W. Gibson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil W. Gibson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil W. Gibson. The network helps show where Neil W. Gibson may publish in the future.

Co-authorship network of co-authors of Neil W. Gibson

This figure shows the co-authorship network connecting the top 25 collaborators of Neil W. Gibson. A scholar is included among the top collaborators of Neil W. Gibson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil W. Gibson. Neil W. Gibson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Henry, Cathérine, Naveen K. Mehta, Kavya Rakhra, et al.. (2025). CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. Journal for ImmunoTherapy of Cancer. 13(4). e008987–e008987. 2 indexed citations

Chau, B. Nelson, et al.. (2013). Therapeutic modulation of microRNAs. Drug Discovery Today Therapeutic Strategies. 10(3). e127–e132. 2 indexed citations

Ma, Wenxue, Alejandro Gutiérrez, Daniel Goff, et al.. (2012). NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. PLoS ONE. 7(6). e39725–e39725. 29 indexed citations

Bhagwat, Shripad V., Prafulla C. Gokhale, Andrew P. Crew, et al.. (2011). Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. Molecular Cancer Therapeutics. 10(8). 1394–1406. 159 indexed citations

Buck, Elizabeth, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, et al.. (2008). Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Research. 68(20). 8322–8332. 164 indexed citations

Barr, Sharon, Stuart Thomson, Elizabeth Buck, et al.. (2008). Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clinical & Experimental Metastasis. 25(6). 685–693. 169 indexed citations

Buck, Elizabeth, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, et al.. (2007). Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1. Molecular Cancer Therapeutics. 6. 1 indexed citations

Ji, Qunsheng, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, et al.. (2007). A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo. Molecular Cancer Therapeutics. 6(8). 2158–2167. 118 indexed citations

Ji, Qunsheng, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, et al.. (2007). Preclinical characterization of OSI-906: A novel IGF-1R kinase inhibitor in clinical trials. Molecular Cancer Therapeutics. 6. 4 indexed citations

10.

Lee, Chong-Soon, Gerd P. Pfeifer, & Neil W. Gibson. (1994). Mapping of DNA alkylation sites induced by aziridinylbenzoquinones in human cells by ligation-mediated polymerase chain reaction.. PubMed. 54(7). 1622–6. 5 indexed citations

11.

Mulcahy, Ríona, et al.. (1994). Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.. PubMed. 54(12). 3196–201. 93 indexed citations

12.

Gibson, Neil W., et al.. (1993). DNA interstrand cross-links induced by the cyclopropylpyrroloindole antitumor agent bizelesin are reversible upon exposure to alkali. Biochemistry. 32(35). 9108–9114. 22 indexed citations

13.

Siegel, David, Howard D. Beall, Masaji Kasai, et al.. (1992). Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 31(34). 7879–7885. 137 indexed citations

14.

Preusch, Peter C., David Siegel, Neil W. Gibson, & David Ross. (1991). A note on the inhibition of DT-diaphorase by dicoumarol. Free Radical Biology and Medicine. 11(1). 77–80. 67 indexed citations

15.

Ross, David, Neil W. Gibson, David Siegel, & Peter C. Preusch. (1990). The role of DT-diaphorase (DTD) in bioreductive activation of the mitomycin class of antitumor quinones. Free Radical Biology and Medicine. 9. 128–128. 1 indexed citations

16.

Gibson, Neil W.. (1989). Alkylating agents: Mechanisms and modulation. Cancer treatment and research. 42. 3–22. 2 indexed citations

17.

Gibson, Neil W., John A. Hartley, John M. Strong, & Kurt W. Kohn. (1986). 2-Chloroethyl (methylsulfonyl)methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas.. PubMed. 46(2). 553–7. 21 indexed citations

18.

Gibson, Neil W., William B. Mattes, & John A. Hartley. (1985). Identification of specific DNA lesions induced by three classes of chloroethylating agents: Chloroethylnitrosoureas, chloroethylmethanesulfonates and chloroethylimidazotetrazines. Pharmacology & Therapeutics. 31(1-2). 153–163. 15 indexed citations

19.

Gibson, Neil W., Leonard C. Erickson, & Kurt W. Kohn. (1985). DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl (methylsulfonyl)methanesulfonate (NSC 338947), a new DNA-chloroethylating agent.. PubMed. 45(4). 1674–9. 16 indexed citations

20.

Gibson, Neil W., et al.. (1981). A comparative study of the anti-tumour activity of N-methylformamide and related compounds.. British Journal of Cancer. 44. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact